The Japanese government has approved its first vaccine against the Covid-19, kick-starting a massive rollout programme for the country of 126 million people.
Pfizer Inc.'s Covid-19 mRNA vaccine got the final approval for emergency use on Sunday from health minister Norihisa Tamura, two days after a government committee gave the shot its seal of approval, paving the way for inoculations to start as early as Wednesday, The Japan Times reported.
The vaccine approvals usually take a year or two, but the government shortened the review period to less than two months, scrapping the requirement for large, third phase clinical trials in Japan amid the mounting toll of the pandemic.
Japan, however, was still the last country among the Group of Seven nations to give it the OK as it required an additional clinical trial to be conducted on Japanese people to ensure safety.
The UK and the US approved the Pfizer shot, jointly developed by the US pharmaceutical giant and Germany's BioNTech SE, in December.
Late-stage trials of Pfizer's vaccine conducted on more than 43,000 participants, of which 5 per cent were Asian, in the US and five other countries have shown that it was 95 per cent effective in preventing Covid-19.
Japan's approval came despite a lack of a large clinical trial in the country, as the number of Covid-19 cases in the country remains significantly lower compared to other countries.
Tamura said Pfizer's clinical trial in Japan on 160 people age 20 to 85 has confirmed the vaccine's effectiveness in producing antibodies in line with the results from the large-scale trial conducted overseas.
The first shipments of Pfizer's vaccines arrived at Narita International Airport from Brussels on Friday, carrying vials for around 400,000 shots, according to Kyodo News. Japan has signed a contract to receive 144 million of Pfizer's vaccines, enough to inoculate 72 million people, by the end of 2021.
--IANS
int/
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)